Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in Advanced Lobular Breast Cancer and CDH1-mutated Tumors
NCT03620643Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- May 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in invasive lobular carcinoma (ILC), diffuse gastric cancer (HDGC), triple-negative breast cancer (TNBC), solid tumor, sponsored by Royal Marsden NHS Foundation Trust. Started May 2019; status: completed.
02
Drugs
crizotinib
03
Conditions
invasive lobular carcinoma (ILC)diffuse gastric cancer (HDGC)triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT03620643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620643.